Heron therapeutics, inc. /de/ (HRTX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Net product sales

25,400

35,083

42,600

36,659

31,600

28,844

19,800

17,277

11,567

10,053

8,572

8,510

3,632

1,279

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

251

395

351

530

Cost of product sales

10,622

15,874

17,195

13,588

14,962

11,572

7,576

5,231

3,133

1,338

1,051

1,013

1,186

35

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

36,894

48,277

34,708

41,425

42,972

39,891

30,421

30,159

39,561

47,757

28,844

28,597

33,384

29,505

30,242

27,286

16,092

16,263

14,241

16,175

14,504

14,195

14,731

14,279

11,628

8,354

6,216

10,806

7,140

5,152

3,626

3,067

3,329

2,855

2,929

1,282

1,141

1,541

1,890

General and administrative

10,422

9,874

8,597

9,778

9,648

8,738

7,288

6,209

7,028

6,165

6,462

6,185

6,742

5,892

5,333

4,774

5,367

6,599

4,127

4,082

3,587

-3,408

4,222

4,512

5,694

5,478

6,448

4,403

5,612

3,476

2,428

1,313

1,440

1,263

1,160

509

569

445

2,335

Sales and marketing

20,196

20,420

16,977

23,647

28,720

19,957

16,281

14,531

13,835

16,683

13,529

14,770

11,619

12,650

12,159

11,006

11,853

8,198

4,123

2,757

2,269

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

78,134

94,445

77,477

88,438

96,302

80,158

61,566

56,130

63,557

71,943

49,886

50,565

52,931

48,082

47,734

43,066

33,312

31,060

22,491

23,014

20,360

19,495

18,953

18,791

17,322

13,832

12,664

15,209

12,752

8,628

6,054

4,380

4,769

4,118

4,089

1,791

1,710

1,986

4,225

Loss from operations

-52,734

-59,362

-34,853

-51,779

-64,700

-51,314

-41,780

-38,853

-51,990

-61,890

-41,314

-42,055

-49,299

-46,803

-47,734

-43,066

-33,312

-31,060

-22,491

-23,014

-20,360

-19,495

-18,953

-18,791

-17,322

-13,832

-12,664

-15,209

-12,752

-8,628

-6,054

-4,380

-4,769

-4,118

-4,089

-1,540

-1,315

-1,635

-3,695

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

3,466

-775

-160

133

-

-

-93

210

-

-

-

-

214

209

204

201

1,007

-195

-146

-61

-47

-62

-263

-1

-1

0

Gain on sale of royalty interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Other income, net

1,155

-4,345

1,258

1,557

1,688

-1,538

3,434

183

-275

2,288

-552

-744

-1,030

-

-

-

-

-

-181

-

-

-

-241

-220

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

-

1,442

-

-

-

1,755

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-216

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,825

-6,249

-4,526

-4,830

-

-4,151

-1,803

-

-1,636

-3,695

Gain from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

128

-43

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,316

-

-

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-91

-

-51

-129

-103

-36

112

Net loss

-51,579

-57,920

-33,595

-50,222

-63,012

-49,559

-38,346

-38,670

-52,265

-62,490

-41,866

-42,799

-50,329

-47,963

-48,509

-43,226

-33,445

-31,242

-22,672

-23,107

-20,570

-20,624

-19,194

-19,011

-17,538

-14,044

-12,873

-15,413

-12,953

-7,737

-6,121

-4,569

-4,921

-4,261

-4,202

-1,932

-1,419

-1,672

-3,583

Other comprehensive income:
Unrealized gains on short-term investments

623

-18

-45

112

123

-45

-17

17

-32

-10

6

24

-13

0

-16

-2

41

-40

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-50,956

-57,938

-33,640

-50,110

-62,889

-49,604

-38,363

-38,653

-52,297

-62,500

-41,860

-42,775

-50,342

-47,963

-48,525

-43,228

-33,404

-31,282

-22,672

-23,107

-20,570

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations (in Dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1.94

-0.02

-0.02

-0.02

-1.80

-0.02

-0.05

-0.03

-0.04

-0.09

Basic and diluted net loss per share

-0.57

-0.65

-0.42

-0.63

-0.80

-0.63

-0.49

-0.54

-0.81

-1.08

-0.77

-0.80

-1.00

-1.23

-1.24

-1.17

-0.92

-0.88

-0.63

-0.74

-0.70

-0.69

-0.66

-0.78

-0.74

-0.72

-0.84

-1.01

-0.85

-1.85

-0.02

-0.02

-0.02

-1.85

-0.02

-0.05

-0.04

-0.04

-0.09

Shares used in computing basic and diluted net loss per share

90,409

89,209

79,940

79,548

78,419

78,285

77,811

71,952

64,724

57,663

54,176

53,791

50,530

39,310

39,113

37,048

36,229

36,124

35,773

31,035

29,392

29,320

29,004

24,266

23,686

18,738

15,375

15,285

15,254

-425,842

274,488

200

200,046

-

-

-

-

-

-

Weighted-average common shares used to compute basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

198

40,016

39

-

-

Shares used to compute basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39,507

39,493